Skip to main content Back to Top
Advertisement

6/4/2025

Octreotide Intramuscular Injection Kits

Products Affected - Description

    • Octreotide Acetate intramuscular injection, Teva, 10 mg, kit, 1 count, NDC 00480-9257-08
    • Octreotide Acetate intramuscular injection, Teva, 20 mg, kit, 1 count, NDC 00480-9259-08
    • Octreotide Acetate intramuscular injection, Teva, 30 mg, kit, 1 count, NDC 00480-9262-08

Reason for the Shortage

    • Novartis has Sandostatin LAR intramuscular injection available.
    • Teva did not provide a reason for the shortage.

Available Products

    • Sandostatin LAR Depot intramuscular injection, Novartis, 10 mg, kit, 1 count, NDC 00078-0811-81
    • Sandostatin LAR Depot intramuscular injection, Novartis, 20 mg, kit, 1 count, NDC 00078-0818-81
    • Sandostatin LAR Depot intramuscular injection, Novartis, 30 mg, kit, 1 count, NDC 00078-0825-81

Estimated Resupply Dates

    • Teva has octreotide 10 mg kits for intramuscular injection on back order and the company estimates a release date in mid-June 2025. The 20 mg and 30 mg kits are on back order and the company estimates a release date of late-June 2025.

Updated

Created June 4, 2025 by Leslie Jensen, PharmD, Drug Information Specialist. © 2025, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.
ADVERTISEMENT